Imunon IncIMNN
Price$1.32

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$14.7MTTM through 30 Jun 2026
Free Cash Flow -$15.7MTTM through 30 Jun 2026

Margins

Current

Returns

-435.7%ROE
-182.5%ROA

Balance Sheet Health

Debt / Equity0.27x
Current Ratio1.59x
Net Debt-$3.9Mnet cash position
Cash & Equivalents$6.9M

Quality Metrics

Altman Z-Score-42.49
Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'17'18'19'20'21'22
FY2022: $500K
Diluted EPS-$2.13TTM
'22'23'24'25
FY2025: $-6.83

Dividend

No dividend

Capital Allocation

R&D Spend$8.2M

Segment Performance

SegmentRevenueYoYOutlook
Non-viral DNA Technology$0
View details

Enrollment in the Phase 3 OVATION 3 Study is expected to be completed by Q1 2029.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.